No Data
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Kain Technology: Keyne Technology 2024 Annual Results Express Announcement
Kain Technology 2024 Annual Results Express Announcement
Kain Technology (688687.SH): Net income for 2024 is 0.144 billion yuan, a year-on-year increase of 23.44%.
On February 27, Gelonghui reported that Kain Technology (688687.SH) announced its performance quick report for the fiscal year 2024. During the reporting period, the company achieved total operating revenue of 1,231.0646 million yuan, a year-on-year decrease of 12.81%; achieved net income attributable to owners of the parent company of 143.8347 million yuan, a year-on-year increase of 23.44%; net income attributable to owners of the parent company after deducting non-recurring gains and losses was 138.4486 million yuan, a year-on-year increase of 12.95%. During the reporting period, the company's core products Jinsuxi and Kain Probiotics' centralized procurement policy was implemented, and the provinces for centralized procurement of glycoside products increased, while
Kain Technology (688687.SH): Currently, a dedicated AI drug research and development team or technology platform has not yet been established.
On February 11, Gelonghui reported that Kain Technology (688687.SH) stated on the investor interaction platform that the company has always focused on the development of cutting-edge technologies in the Industry regarding the application of AI technology in drug research and development, but has not yet established a dedicated AI drug research and development team or technical platform.
